MammaPrint utilizes 70 genes to report a good or bad prognosis for each patient, and was developed from microarray experiments to predict 5-year metastatic recurrence of breast cancer as a first event among ER positive and negative patients [9,10]. Here, ESR1 is linked to breast cancer.